The IBD SmartSelect Composite Rating for Eton Pharmaceuticals increased from 93 to 96 Tuesday.
Discover The 3 Keys To Successful Stock Investing
The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
Eton Pharmaceuticals is currently forming a cup with handle, with a 17.74 buy point. See if the stock can break out in volume at least 40% above average. But note that it's a later-stage base, and those involve more risk. Be aware that it's a thinly traded stock, with average daily dollar volume under $8 million. Such stocks may show wider daily or weekly fluctuations than stocks with greater trading volume.
One weak spot is the company's 68 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A- shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.
The company reported a 0% increase in earnings for Q4. Sales growth climbed 59%, up from 47% in the prior report. That marks two consecutive reports with increasing revenue gains. The company's next quarterly report is expected on or around May. 13.
Eton Pharmaceuticals holds the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
